Template:Oral hypoglycemics and insulin analogs: Difference between revisions
Content deleted Content added
Berchanhimez (talk | contribs) organize better to separate insulin (analogs) from non-insulin drugs. |
|||
| (41 intermediate revisions by 14 users not shown) | |||
| Line 1: | Line 1: | ||
{{Navbox with collapsible groups |
{{Navbox with collapsible groups |
||
| name = Oral hypoglycemics and insulin analogs |
| name = Oral hypoglycemics and insulin analogs |
||
| title = Oral [[ |
| title = Oral [[diabetes medication]], [[insulin]]s and [[insulin analog]]s, and other drugs used in diabetes ([[ATC code A10|A10]]) |
||
| state = {{{state<includeonly>|expanded</includeonly>}}} |
| state = {{{state<includeonly>|expanded</includeonly>}}} |
||
| listclass = hlist |
| listclass = hlist |
||
| group1 = [[Insulin]]s/[[insulin analog]]s |
| group1 = [[Insulin]]s / [[insulin analog]]s |
||
| list1 = {{Navbox|child |
| list1 = {{Navbox|child |
||
| group1 = ''fast-acting'' |
| group1 = ''fast-acting'' |
||
| list1= |
| list1= |
||
*[[Insulin aspart]] |
* [[Insulin aspart]] |
||
*[[Insulin glulisine]] |
* [[Insulin glulisine]] |
||
*[[Insulin lispro]] |
* [[Insulin lispro]] |
||
| group2 = ''short-acting'' |
| group2 = ''short-acting'' |
||
| list2 = |
| list2 = |
||
*[[Regular insulin]] |
* [[Regular insulin]]<sup>#</sup> |
||
| group3 = ''long-acting'' |
| group3 = ''long-acting'' |
||
| list3 = |
| list3 = |
||
*[[Insulin detemir]] |
* [[Insulin detemir]]<sup>#</sup> |
||
*[[Insulin glargine]] ([[Insulin glargine/lixisenatide|+lixisenatide]]) |
* [[Insulin glargine]]<sup>#</sup> ([[Insulin glargine/lixisenatide|+lixisenatide]]) |
||
*[[NPH insulin]] |
* [[NPH insulin]] |
||
*[[Lente insulin]]<sup>‡</sup> |
* [[Lente insulin]]<sup>‡</sup> |
||
*[[Ultralente insulin]]<sup>‡</sup> |
* [[Ultralente insulin]]<sup>‡</sup> |
||
| group4 = ''ultra-long-acting'' |
| group4 = ''ultra-long-acting'' |
||
| list4 = |
| list4 = |
||
*[[Insulin degludec]] ([[Insulin degludec/liraglutide|+liraglutide]]) |
* [[Insulin degludec]]<sup>#</sup> ([[Insulin degludec/insulin aspart|+insulin aspart]], [[Insulin degludec/liraglutide|+liraglutide]]) |
||
* [[Insulin icodec]]<sup>†</sup> ([[Insulin icodec/semaglutide|+semaglutide]]) |
|||
| group5 = ''[[Inhalable insulin|inhalable]]'' |
| group5 = ''[[Inhalable insulin|inhalable]]'' |
||
| list5 = |
| list5 = |
||
*Exubera<sup>‡</sup> |
* Exubera<sup>‡</sup> |
||
* Afrezza |
|||
*Afreeza |
|||
}} |
}} |
||
{{PharmNavFootnote}} |
|||
| group2 = Non-insulins |
| group2 = Non-insulins |
||
| Line 43: | Line 45: | ||
| group1 = [[Biguanide]]s |
| group1 = [[Biguanide]]s |
||
| list1 = |
| list1 = |
||
*[[Buformin]]<sup>‡</sup> |
* [[Buformin]]<sup>‡</sup> |
||
*[[Metformin]]<sup>#</sup> |
* [[Metformin]]<sup>#</sup> |
||
*[[Phenformin]]<sup>‡</sup> |
* [[Phenformin]]<sup>‡</sup> |
||
| group2 = [[Thiazolidinedione|TZD]]s/"glitazones" ([[PPAR agonist|PPAR]]) |
| group2 = [[Thiazolidinedione|TZD]]s/"glitazones" ([[PPAR agonist|PPAR]]) |
||
| list2 = |
| list2 = |
||
*[[Ciglitazone]]<sup>§</sup> |
* [[Ciglitazone]]<sup>§</sup> |
||
*[[Darglitazone]]<sup>§</sup> |
* [[Darglitazone]]<sup>§</sup> |
||
*[[Englitazone]]<sup>§</sup> |
* [[Englitazone]]<sup>§</sup> |
||
*[[Lobeglitazone]] |
* [[Lobeglitazone]] |
||
*[[Netoglitazone]]<sup>§</sup> |
* [[Netoglitazone]]<sup>§</sup> |
||
*[[Pioglitazone]] |
* [[Pioglitazone]] |
||
*[[Rivoglitazone]]<sup>†</sup> |
* [[Rivoglitazone]]<sup>†</sup> |
||
*[[Rosiglitazone]] |
* [[Rosiglitazone]] |
||
*[[Troglitazone]]<sup>‡</sup> |
* [[Troglitazone]]<sup>‡</sup> |
||
| group3 = [[PPAR agonist#Dual PPAR agonists|Dual PPAR agonists]] |
| group3 = [[PPAR agonist#Dual PPAR agonists|Dual PPAR agonists]] |
||
| list3 = |
| list3 = |
||
*[[Aleglitazar]]<sup>†</sup> |
* [[Aleglitazar]]<sup>†</sup> |
||
*[[Muraglitazar]]<sup>§</sup> |
* [[Muraglitazar]]<sup>§</sup> |
||
*[[Saroglitazar]] |
* [[Saroglitazar]] |
||
*[[Tesaglitazar]]<sup>§</sup> |
* [[Tesaglitazar]]<sup>§</sup> |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
}} |
}} |
||
| Line 77: | Line 84: | ||
| group1 = [[Sulfonylurea]]s |
| group1 = [[Sulfonylurea]]s |
||
| list1 = |
| list1 = |
||
*''1st generation'': [[Acetohexamide]] |
* ''1st generation'': [[Acetohexamide]] |
||
*[[Carbutamide]] |
* [[Carbutamide]] |
||
*[[Chlorpropamide]] |
* [[Chlorpropamide]] |
||
*[[Glycyclamide]] |
* [[Glycyclamide]] |
||
*[[Metahexamide]] |
* [[Metahexamide]] |
||
*[[Tolazamide]] |
* [[Tolazamide]] |
||
*[[Tolbutamide]] |
* [[Tolbutamide]] |
||
*''2nd generation'': [[Glibenclamide|Glibenclamide (glyburide)]] |
* ''2nd generation'': [[Glibenclamide|Glibenclamide (glyburide)]] |
||
*[[Glibornuride]] |
* [[Glibornuride]] |
||
*[[Glicaramide]] |
* [[Glicaramide]] |
||
*[[Gliclazide]]<sup>#</sup> |
* [[Gliclazide]]<sup>#</sup> |
||
*[[Glimepiride]] |
* [[Glimepiride]] |
||
*[[Glipizide]] |
* [[Glipizide]] |
||
*[[Gliquidone]] |
* [[Gliquidone]] |
||
*[[Glisoxepide]] |
* [[Glisoxepide]] |
||
*[[Glyclopyramide]] |
* [[Glyclopyramide]] |
||
| group2 = [[Meglitinide]]s/"glinides" |
| group2 = [[Meglitinide]]s/"glinides" |
||
| list2 = |
| list2 = |
||
*[[Mitiglinide]] |
* [[Mitiglinide]] |
||
*[[Nateglinide]] |
* [[Nateglinide]] |
||
*[[Repaglinide]] |
* [[Repaglinide]] |
||
}} |
}} |
||
| Line 105: | Line 112: | ||
| group2 = [[Glucagon-like peptide-1 receptor agonist|GLP-1 receptor agonists]] |
| group2 = [[Glucagon-like peptide-1 receptor agonist|GLP-1 receptor agonists]] |
||
| list2 = |
| list2 = |
||
*[[Albiglutide]]<sup>‡</sup> |
* [[Albiglutide]]<sup>‡</sup> |
||
* [[Danuglipron]]<sup>†</sup> |
|||
*[[Dulaglutide]] |
|||
*[[ |
* [[Dulaglutide]] |
||
*[[ |
* [[Exenatide]] |
||
*[[ |
* [[Liraglutide]] |
||
*[[ |
* [[Lixisenatide]] |
||
*[[ |
* [[Orforglipron]]<sup>§</sup> |
||
* [[Semaglutide]] |
|||
* [[Taspoglutide]]<sup>†</sup> |
|||
{{navbox|child| |
|||
group1=[[GLP1 poly-agonist peptides]] |
|||
|list1= |
|||
* [[Mazdutide]] (GLP-1/[[Glucagon receptor|GCGR]]) |
|||
* [[Retatrutide]]<sup>§</sup> (GLP-1/GIP/GCGR) |
|||
* [[Tirzepatide]] (GLP-1/GIP) |
|||
}} |
|||
| group3 = [[Dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitor]]s/"gliptins" |
| group3 = [[Dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitor]]s/"gliptins" |
||
| list3 = |
| list3 = |
||
*[[Alogliptin]] |
* [[Alogliptin]] |
||
*[[Anagliptin]] |
* [[Anagliptin]] |
||
*[[Evogliptin]] |
* [[Evogliptin]] |
||
*[[Garvagliptin]] |
* [[Garvagliptin]] |
||
*[[Gemigliptin]] |
* [[Gemigliptin]] |
||
*[[Gosogliptin]] |
* [[Gosogliptin]] |
||
*[[Linagliptin]] |
* [[Linagliptin]] |
||
*[[Melogliptin]] |
* [[Melogliptin]] |
||
*[[Omarigliptin]] |
* [[Omarigliptin]] |
||
*[[ |
* [[Retagliptin]] |
||
*[[ |
* [[Saxagliptin]] |
||
*[[ |
* [[Sitagliptin]] |
||
*[[ |
* [[Teneligliptin]] |
||
*[[ |
* [[Trelagliptin]] |
||
* [[Vildagliptin]] |
|||
| group4 = [[Free fatty acid receptor 1| FFAR1 agonists]] |
|||
| ⚫ | |||
| ⚫ | |||
}} |
}} |
||
|group3 = Other |
|group3 = Other |
||
| Line 138: | Line 150: | ||
| group1 = [[Aldose reductase inhibitor]]s |
| group1 = [[Aldose reductase inhibitor]]s |
||
| list1 = |
| list1 = |
||
*[[Epalrestat]] |
* [[Epalrestat]] |
||
*[[Fidarestat]]<sup>§</sup> |
* [[Fidarestat]]<sup>§</sup> |
||
*[[Ranirestat]]<sup>†</sup> |
* [[Ranirestat]]<sup>†</sup> |
||
*[[Tolrestat]]<sup>‡</sup> |
* [[Tolrestat]]<sup>‡</sup> |
||
*[[Zenarestat]]<sup>§</sup> |
* [[Zenarestat]]<sup>§</sup> |
||
| group2 = [[Alpha-glucosidase inhibitor]]s |
| group2 = [[Alpha-glucosidase inhibitor]]s |
||
| list2 = |
| list2 = |
||
*[[Acarbose]] |
* [[Acarbose]] |
||
*[[Miglitol]] |
* [[Miglitol]] |
||
*[[Voglibose]] |
* [[Voglibose]] |
||
| ⚫ | |||
| list3 = |
|||
| ⚫ | |||
| group4 = [[Gliflozin|SGLT2 inhibitors]]/"gliflozins" |
| group4 = [[Gliflozin|SGLT2 inhibitors]]/"gliflozins" |
||
| list4 = |
| list4 = |
||
*[[Canagliflozin]] |
* [[Canagliflozin]] |
||
*[[Dapagliflozin]] |
* [[Dapagliflozin]] |
||
*[[Empagliflozin]] |
* [[Empagliflozin]]<sup>#</sup> |
||
*[[Ertugliflozin]] |
* [[Ertugliflozin]] |
||
*[[Ipragliflozin]] |
* [[Ipragliflozin]] |
||
* [[Luseogliflozin]] |
|||
*[[Remogliflozin etabonate|Remogliflozin]]<sup>§</sup> |
|||
*[[ |
* [[Remogliflozin etabonate|Remogliflozin]]<sup>§</sup> |
||
*[[ |
* [[Sergliflozin etabonate|Sergliflozin]]<sup>§</sup> |
||
* [[Sotagliflozin]] |
|||
* [[Tofogliflozin]]<sup>†</sup> |
|||
* [[Velagliflozin]] |
|||
| group5 = Other |
| group5 = Other |
||
| list5 = |
| list5 = |
||
*[[Benfluorex]]<sup>‡</sup> |
* [[Benfluorex]]<sup>‡</sup> |
||
*[[Bromocriptine]] |
* [[Bromocriptine]] |
||
* [[Imeglimin]] |
|||
}} |
}} |
||
|group4 = [[Combination drug|Combinations]] |
|group4 = [[Combination drug|Combinations]] |
||
| Line 174: | Line 186: | ||
|list1 = |
|list1 = |
||
* [[Alogliptin/metformin]] |
* [[Alogliptin/metformin]] |
||
* [[Canagliflozin/metformin]] |
|||
* [[Cagrilintide/semaglutide]]<sup>§</sup> |
|||
* [[Dapagliflozin/metformin]] |
|||
* [[Dapagliflozin/saxagliptin]] |
|||
| ⚫ | |||
* [[Empagliflozin/linagliptin]] |
|||
* [[Empagliflozin/metformin]] |
|||
* [[Gemigliptin/rosuvastatin]] |
* [[Gemigliptin/rosuvastatin]] |
||
* [[Glibenclamide/metformin|Glibenclamide (glyburide)/metformin]] |
|||
* [[Glimepiride/pioglitazone]] |
|||
* [[Glimepiride/rosiglitazone]] |
* [[Glimepiride/rosiglitazone]] |
||
* [[Insulin degludec/insulin aspart]] |
|||
* [[Insulin degludec/liraglutide]] |
|||
* [[Insulin glargine/lixisenatide]] |
|||
* [[Linagliptin/empagliflozin]] |
|||
* [[Linagliptin/metformin]] |
* [[Linagliptin/metformin]] |
||
* [[Metformin/acarbose]] |
* [[Metformin/acarbose]] |
||
* [[Metformin/canagliflozin]] |
|||
* [[Metformin/dapagliflozin]] |
|||
* [[Metformin/empagliflozin]] |
|||
* [[Metformin/ertugliflozin]] |
* [[Metformin/ertugliflozin]] |
||
* [[Metformin/evogliptin]] |
* [[Metformin/evogliptin]] |
||
* [[Metformin/gemigliptin]] |
* [[Metformin/gemigliptin]] |
||
* [[Metformin/pioglitazone]] |
|||
* [[Metformin/repaglinide]] |
* [[Metformin/repaglinide]] |
||
| ⚫ | |||
* [[Metformin/sulfonylureas]] |
* [[Metformin/sulfonylureas]] |
||
* [[Metformin/ |
* [[Metformin/teneligliptin]] |
||
* [[Phenformin/sulfonylureas]] |
* [[Phenformin/sulfonylureas]] |
||
* [[Pioglitazone/alogliptin]] |
* [[Pioglitazone/alogliptin]] |
||
* [[Pioglitazone/glimepiride]] |
|||
* [[Pioglitazone/metformin]] |
|||
* [[Pioglitazone/sitagliptin]] |
* [[Pioglitazone/sitagliptin]] |
||
* [[Rosiglitazone/metformin]] |
* [[Rosiglitazone/metformin]] |
||
* [[Saxagliptin/dapagliflozin]] |
|||
* [[Saxagliptin/metformin]] |
* [[Saxagliptin/metformin]] |
||
* [[Dapagliflozin/sitagliptin|Sitagliptin/dapagliflozin]] |
|||
* [[Sitagliptin/ertugliflozin]] |
* [[Sitagliptin/ertugliflozin]] |
||
* [[Sitagliptin/metformin]] |
* [[Sitagliptin/metformin]] |
||
* [[Sitagliptin/simvastatin]] |
* [[Simvastatin/sitagliptin|Sitagliptin/simvastatin]] |
||
* [[Vildagliptin/metformin]] |
|||
}} |
}} |
||
}} |
}} |
||
{{PharmNavFootnote}} |
|||
}} |
}} |
||
<noinclude> |
<noinclude> |
||
Latest revision as of 20:21, 3 January 2025
This template's initial visibility currently defaults to autocollapse, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible.
To change this template's initial visibility, the |state= parameter may be used:
{{Oral hypoglycemics and insulin analogs|state=collapsed}}will show the template collapsed, i.e. hidden apart from its title bar.{{Oral hypoglycemics and insulin analogs|state=expanded}}will show the template expanded, i.e. fully visible.